Predictors of survival in patients with extensive-stage small-cell lung cancer

Lead Investigator: Sinbad Xia, Zhejiang University School of Medicine
Title of Proposal Research: Predictors of survival in patients with extensive-stage small-cell lung cancer
Vivli Data Request: 9389
Funding Source: This work will be supported by grants from Zhejiang Provincial Clinical Research Center for Respiratory Disease (2022E50005) and Natural Science Foundation of Zhejiang Province (No.LY23H160020), Medicine Health Technology Plan of Zhejiang Province, China (No. 2022KY150), and General Project of Education Department of Zhejiang Province (Y202043420).
Potential Conflicts of Interest: None

Summary of the Proposed Research:

Small cell lung cancer (SCLC) is a type of lung cancer where cancer cells form in the tissue of the lungs and accounts for approximately 14% of all lung cancer cases. SCLC is also the histologic type with the poorest prognosis, with a 5-year survival rates of 5%-10%. Extensive-stage SCLC (ES-SCLC) presents in approximately two-thirds of all SCLCs and is characterized by its rapid growth rate, tumor extension that includes more than half the chest, metastasis to other parts of the body, or cannot be surrounded by standard radiotherapy.
This study aims to find out what factors can help patients with ES-SCLC live longer when they receive a type of treatment called immune checkpoint inhibitors (ICI), a type of drug that works by blocking proteins that stop the immune system from attacking cancer cells These inhibitors are like special medicines that help the body’s own immune system fight against cancer. We want to identify specific things about the patients or their cancer that might influence how well they respond to this treatment. By understanding these factors, doctors can better predict who might benefit the most from ICI. This research could lead to more personalized and effective treatments for people with ES-SCLC, giving them a better chance at living longer and healthier lives.

Requested Studies:

A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
Data Contributor: Roche
Study ID: NCT02763579
Sponsor ID: GO30081